The project – the European Drug Initiative for Channels and Transporters (EDICT) – will target about 80 proteins, which play an important role in human diseases as varied as diabetes, heart disease, neuropsychiatric disorders like epilepsy and depression, osteoporosis, stomach ulcers and cataracts.
Membrane proteins are key to every process in the human body, channelling ions or transporting chemicals and so are ideal targets for new treatments. Infections by pathogenic bacteria, yeasts and parasites also involve their own membrane proteins, which can be specific targets for development of new drugs and antibiotics.
The research is mainly funded by the European Commission, involves twenty-seven partners from twelve countries – including two Nobel Laureates - and is set to last four years.
Coordinating the project is Peter Henderson, Professor of Biochemistry and Molecular Biology from Leeds’ Faculty of Biological Sciences.
“Membrane proteins are seen by many as the next potential source of drug development, and so the EC is keen to fund research in this area,” he said. “However, they are difficult to study and are poorly understood, though the recent sequencing of the human and other genomes show they make up about one third of all proteins in all organisms, including humans.”
“At the moment, few groups of membrane proteins are being seriously investigated by the pharmaceutical industry, so this project will help to fill that gap. By bringing together the best scientists in this challenging field from all over Europe, we hope to make a real advance towards new treatments for key diseases.”
Industry has also seen the benefit of bringing such expertise together under one umbrella and working with the academics will be pharmaceutical giant AstraZeneca and a smaller company, Xention, which specialises in the discovery and development of novel and selective ion channel drugs.
The researchers include biologists, structural biologists, chemists and experts in the three key technologies: x-ray crystallography, nuclear magnetic resonance, and electron microscopy.
The team aims to map out the structure of the proteins, so they can identify compounds that could be developed as a treatment for these diseases. Where they have already mapped some structures, the team will have a head start and hope to make real advances towards new treatments.
Other researchers joining the project from Leeds include Professors Steve Baldwin and Carola Hunte from the Faculty of Biological Sciences and Professor Peter Johnson and Dr Colin Fishwick from the School of Chemistry. All are members of Leeds’ Astbury Centre, the leading interdisciplinary research centre in the UK studying how life works at an atomic level.
The two Nobel Laureates involved in the research are Director of the Medical Research Council’s Dunn Human Nutrition Unit in Cambridge, Professor Sir John Walker, who also holds an honorary doctorate from the University of Leeds, and Director of the Max Planck Institute for Biophysics in Frankfurt, Germany, Professor Hartmut Michel.
Jo Kelly | alfa
Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University
Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
22.08.2017 | Health and Medicine
22.08.2017 | Materials Sciences
22.08.2017 | Life Sciences